Source:http://linkedlifedata.com/resource/pubmed/id/20493435
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
2010-5-24
|
| pubmed:abstractText |
Pharmaceutical research and development in France is an important and dynamic economic sector that places France among the countries most involved in research. However, economic constraints have precipitated major changes in this industry. The costs associated with the genesis of a drug, from discovery to marketing, are increasing, forcing the industry to adapt. Here we discuss the motivations of the pharmaceutical industry in oncology so that the medico-surgical specialist of the cancers of the genito-urinary tract can best understand the situation.
|
| pubmed:language |
fre
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1166-7087
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20 Suppl 1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
S1-4
|
| pubmed:meshHeading | |
| pubmed:year |
2010
|
| pubmed:articleTitle |
[The journey of a molecule, from trials to approval: the specific area of oncology].
|
| pubmed:affiliation |
Service d'urologie, Hôpital Foch, rue Worth, Suresnes, France. t.lebret@hopital-foch.org
|
| pubmed:publicationType |
Journal Article,
English Abstract
|